Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Dies

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Immunity & Ageing : I & A|May 14, 2014
LATEX sensitization in elderly: allergological study and diagnostic protocolTeresa Grieco, Valentina Faina, Laura Dies, et al.
Immunotherapy|September 7, 2020
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatmentTeresa Grieco, Laura Dies, Alvise Sernicola, et al.
Clinical and Molecular Allergy : CMA|March 27, 2019
Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patientSusanna Bormioli, Andrea Matucci, Laura Dies, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 17, 2020
Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reactionAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Scientific Reports|June 16, 2021
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
European Journal of Gastroenterology & Hepatology|April 13, 2018
Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseasesMichele Spinicci, Giacomo Emmi, Laura Dies, et al.
Allergy, Asthma & Immunology Research|July 9, 2020
Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With PolyangiitisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Frontiers in Immunology|January 29, 2019
T Cell Response to Infliximab in Exposed Patients: A Longitudinal AnalysisSara Pratesi, Francesca Nencini, Francesca Grosso, et al.
Dermatologic Therapy|December 22, 2019
A severe adverse reaction to omalizumab therapy in chronic spontaneous urticariaLaura Dies, Alvise Sernicola, Francesca Magri, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Immunity & Ageing : I & A|May 14, 2014
LATEX sensitization in elderly: allergological study and diagnostic protocolTeresa Grieco, Valentina Faina, Laura Dies, et al.
Immunotherapy|September 7, 2020
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatmentTeresa Grieco, Laura Dies, Alvise Sernicola, et al.
Clinical and Molecular Allergy : CMA|March 27, 2019
Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patientSusanna Bormioli, Andrea Matucci, Laura Dies, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 17, 2020
Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reactionAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Scientific Reports|June 16, 2021
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
European Journal of Gastroenterology & Hepatology|April 13, 2018
Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseasesMichele Spinicci, Giacomo Emmi, Laura Dies, et al.
Allergy, Asthma & Immunology Research|July 9, 2020
Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With PolyangiitisAlessandra Vultaggio, Francesca Nencini, Susanna Bormioli, et al.
Frontiers in Immunology|January 29, 2019
T Cell Response to Infliximab in Exposed Patients: A Longitudinal AnalysisSara Pratesi, Francesca Nencini, Francesca Grosso, et al.
Dermatologic Therapy|December 22, 2019
A severe adverse reaction to omalizumab therapy in chronic spontaneous urticariaLaura Dies, Alvise Sernicola, Francesca Magri, et al.
Frontiers in Immunology|June 14, 2018
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's SyndromeAndrea Matucci, Francesco Liotta, Emanuele Vivarelli, et al.
Pageof 1